{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:29:00Z","timestamp":1759336140138},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10388-020-00731-y","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T11:03:06Z","timestamp":1584097386000},"page":"425-432","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients"],"prefix":"10.1007","volume":"17","author":[{"given":"Terufumi","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Shikama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Mine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tsurumaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Sasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"731_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1007\/s00268-012-1762-2","volume":"36","author":"Z Faiz","year":"2012","unstructured":"Faiz Z, Lemmens VE, Siersema PD, Nieuwenhuijzen GA, Wouters MW, Rozema T, et al. Increased resection rates and survival among patients aged 75 years and older with esophageal cancer: a Dutch nationwide population-based study. World J Surg. 2012;36:2872\u20138.","journal-title":"World J Surg"},{"key":"731_CR2","unstructured":"National Cancer Center in Japan. Center for Cancer Control and Information Services. Available at: https:\/\/ganjoho.jp\/reg_stat\/index.html. 2017."},{"key":"731_CR3","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1053\/j.ajkd.2009.09.035","volume":"55","author":"LA Stevens","year":"2010","unstructured":"Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the kidney early evaluation program (KEEP). Am J Kidney Dis. 2010;55:S23\u201333.","journal-title":"Am J Kidney Dis"},{"key":"731_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68\u201374.","journal-title":"Ann Surg Oncol"},{"key":"731_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","volume":"81","author":"K Kato","year":"2011","unstructured":"Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"731_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u201301) Radiation Therapy Oncology Group. JAMA. 1999;281:1623\u20137.","journal-title":"JAMA"},{"key":"731_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/jjco\/hyt048","volume":"43","author":"K Kato","year":"2013","unstructured":"Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013;43:608\u201315.","journal-title":"Jpn J Clin Oncol."},{"key":"731_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12622","volume":"106","author":"M Shinoda","year":"2015","unstructured":"Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407\u201312.","journal-title":"Cancer Sci"},{"key":"731_CR9","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/cas.12764","volume":"106","author":"M Tahara","year":"2015","unstructured":"Tahara M, Fuse N, Mizusawa J, Sato A, Nihei K, Kanato K, et al. Phase I\/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II\/III esophageal carcinoma (JCOG 0604). Cancer Sci. 2015;106:1414\u201320.","journal-title":"Cancer Sci"},{"key":"731_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/COC.0b013e3180ca7c84","volume":"30","author":"S Takeuchi","year":"2007","unstructured":"Takeuchi S, Ohtsu A, Doi T, Kojima T, Minashi K, Mera K, et al. A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol. 2007;30:607\u201311.","journal-title":"Am J Clin Oncol"},{"key":"731_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02993858","volume":"13","author":"AI Einzig","year":"1996","unstructured":"Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996;13:87\u201393.","journal-title":"Med Oncol"},{"key":"731_CR12","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1053\/j.seminoncol.2005.04.005","volume":"32","author":"JR Rigas","year":"2005","unstructured":"Rigas JR, Dragnev KH, Bubis JA. Docetaxel in the treatment of esophageal cancer. Semin Oncol. 2005;32:S39\u201351.","journal-title":"Semin Oncol"},{"key":"731_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","volume":"36","author":"SJ Clarke","year":"1999","unstructured":"Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99\u2013114.","journal-title":"Clin Pharmacokinet"},{"key":"731_CR14","first-page":"1842","volume":"56","author":"C Hennequin","year":"1996","unstructured":"Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996;56:1842\u201350.","journal-title":"Cancer Res"},{"key":"731_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3727\/0965040041791455","volume":"14","author":"AL Dunne","year":"2004","unstructured":"Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG. Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action. Oncol Res. 2004;14:447\u201354.","journal-title":"Oncol Res"},{"key":"731_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1200\/JCO.1998.16.1.159","volume":"16","author":"AM Mauer","year":"1998","unstructured":"Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998;16:159\u201364.","journal-title":"J Clin Oncol"},{"key":"731_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/dote.12105","volume":"27","author":"T Kushida","year":"2014","unstructured":"Kushida T, Nohara S, Yoshino K, Fujiwara D, Ouchi K, Amano T, et al. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis. Dis Esophagus. 2014;27:368\u201373.","journal-title":"Dis Esophagus"},{"key":"731_CR18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0959-8049(97)10101-0","volume":"34","author":"MI Koukourakis","year":"1998","unstructured":"Koukourakis MI, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A I\/II phase dose escalation trial. Eur J Cancer. 1998;34:838\u201344.","journal-title":"Eur J Cancer"},{"key":"731_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0360-3016(03)01370-1","volume":"58","author":"G Calais","year":"2004","unstructured":"Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B, et al. Radiotherapy with concomitant weekly docetaxel for Stages III\/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys. 2004;58:161\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"731_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10147-003-0375-z","volume":"9","author":"M Fujii","year":"2004","unstructured":"Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, et al. Phase I\/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol. 2004;9:107\u201312.","journal-title":"Int J Clin Oncol"},{"key":"731_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12094-007-0032-5","volume":"9","author":"A Font","year":"2007","unstructured":"Font A, Arellano A, Fernandez-Llamazares J, Casas D, Boix J, Cardenal J, et al. Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Transl Oncol. 2007;9:177\u201382.","journal-title":"Clin Transl Oncol"},{"key":"731_CR22","unstructured":"Hokamura N, Kawano N, Takmaki Y. A phase I study of docetaxel with concurrent radiotherapy in patients with esophageal cancer. In: 18th World Congress, World Society of Cardio-Thoracic Surgeons. 2008."},{"key":"731_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.08.009","author":"T Kawamoto","year":"2019","unstructured":"Kawamoto T, Shikama N, Oshima M, Kosugi Y, Tsurumaru M, Sasai K. Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer. J Geriatr Oncol. 2019. https:\/\/doi.org\/10.1016\/j.jgo.2019.08.009.","journal-title":"J Geriatr Oncol"},{"key":"731_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.adro.2016.07.002","volume":"1","author":"A Ohba","year":"2016","unstructured":"Ohba A, Kato K, Ito Y, Katada C, Ishiyama H, Yamamoto S, et al. Chemoradiation therapy with docetaxel in elderly patients with stage II\/III esophageal cancer: A phase 2 trial. Adv Radiat Oncol. 2016;1:230\u20136.","journal-title":"Adv Radiat Oncol"},{"key":"731_CR25","unstructured":"Common Toxicity Criteria, Version2.0 Publish Date April 30. 1999."},{"key":"731_CR26","unstructured":"Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. In: Chichester 8th ed. John Wiley & Sons, Inc: West Sussex, Hoboken, 2017."},{"key":"731_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"731_CR28","unstructured":"National Cancer Institute (U.S.). Common terminology criteria for adverse events (CTCAE). Rev. ed. Bethesda, Md.: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009."},{"key":"731_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","journal-title":"Am J Epidemiol"},{"key":"731_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"731_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82:777\u201383.","journal-title":"Am J Clin Nutr"},{"key":"731_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MCO.0b013e3283186f59","volume":"12","author":"E Cereda","year":"2009","unstructured":"Cereda E, Pedrolli C. The Geriatric Nutritional Risk Index. Curr Opin Clin Nutr Metab Care. 2009;12:1\u20137.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"731_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1532-5415.1995.tb05803.x","volume":"43","author":"JI Wallace","year":"1995","unstructured":"Wallace JI, Schwartz RS, LaCroix AZ, Uhlmann RF, Pearlman RA. Involuntary weight loss in older outpatients: incidence and clinical significance. J Am Geriatr Soc. 1995;43:329\u201337.","journal-title":"J Am Geriatr Soc"},{"key":"731_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"731_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/scipharm85010008","volume":"85","author":"T Hendrayana","year":"2017","unstructured":"Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer dose adjustment for patients with renal and hepatic dysfunction: from scientific evidence to clinical application. Sci Pharm. 2017;85:8.","journal-title":"Sci Pharm"},{"key":"731_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"731_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1442-2050.2009.01014.x","volume":"23","author":"RH Mak","year":"2010","unstructured":"Mak RH, Mamon HJ, Ryan DP, Miyamoto DT, Ancukiewicz M, Kobayashi WK, et al. Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Dis Esophagus. 2010;23:316\u201323.","journal-title":"Dis Esophagus"},{"key":"731_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0090-4295(98)00150-2","volume":"52","author":"MA Dimopoulos","year":"1998","unstructured":"Dimopoulos MA, Deliveliotis C, Moulopoulos LA, Papadimitriou C, Mitropoulos D, Anagnostopoulos A, et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology. 1998;52:56\u201360.","journal-title":"Urology"},{"key":"731_CR39","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1111\/1759-7714.13222","volume":"10","author":"S Anai","year":"2019","unstructured":"Anai S, Ibusuki R, Takao T, Sakurai Y, Hisasue J, Takaki Y, et al. Retrospective cohort study on the safety and efficacy of docetaxel in Japanese non-small cell lung cancer patients with nondialysis chronic kidney disease stage 3b or higher. Thorac Cancer. 2019;10:2282\u20138.","journal-title":"Thorac Cancer"},{"key":"731_CR40","first-page":"1077","volume":"9","author":"R Bruno","year":"2003","unstructured":"Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res. 2003;9:1077\u201382.","journal-title":"Clin Cancer Res"},{"key":"731_CR41","doi-asserted-by":"publisher","first-page":"e0155903","DOI":"10.1371\/journal.pone.0155903","volume":"11","author":"Y Bo","year":"2016","unstructured":"Bo Y, Wang K, Liu Y, You J, Cui H, Zhu Y, et al. The geriatric nutritional risk index predicts survival in elderly esophageal squamous cell carcinoma patients with radiotherapy. PLoS ONE. 2016;11:e0155903.","journal-title":"PLoS ONE"},{"key":"731_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13014-018-1044-8","volume":"13","author":"F Walter","year":"2018","unstructured":"Walter F, Bockle D, Schmidt-Hegemann NS, Kopple R, Gerum S, Boeck S, et al. Clinical outcome of elderly patients (%3e\/= 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio (chemo) therapy: a retrospective single center analysis. Radiat Oncol. 2018;13:93.","journal-title":"Radiat Oncol"},{"key":"731_CR43","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.7314\/APJCP.2015.16.4.1463","volume":"16","author":"X Li","year":"2015","unstructured":"Li X, Zhao LJ, Liu NB, Zhang WC, Pang QS, Wang P, et al. Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution. Asian Pac J Cancer Prev. 2015;16:1463\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"731_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3143\/geriatrics.44.90","volume":"44","author":"S Hirayama","year":"2007","unstructured":"Hirayama S, Kikuchi R, Inoue S, Tsukahara D, Suemitsu Y, Kobayashi Y, et al. Creatinine clearance estimation in the extremely elderly subjects. Nihon Ronen Igakkai Zasshi. 2007;44:90\u20134.","journal-title":"Nihon Ronen Igakkai Zasshi."}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10388-020-00731-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:56:28Z","timestamp":1615596988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10388-020-00731-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1007\/s10388-020-00731-y","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"23 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the Helsinki declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}